Verge Genomics 和 Ferrer 合作在选定地区共同开发 ALS 药物 VRG50635。 Verge Genomics and Ferrer partner to co-develop ALS drug VRG50635 in selected regions.
Verge Genomics 和专注于罕见神经系统疾病的制药公司 Ferrer 宣布开展战略合作，共同开发 VRG50635，这是一种用于治疗散发性和家族性肌萎缩侧索硬化症 (ALS) 的临床阶段药物。 Verge Genomics and Ferrer, a rare neurological disorder-focused pharmaceutical company, have announced a strategic collaboration to co-develop VRG50635, a clinical-stage drug for treating sporadic and familial forms of amyotrophic lateral sclerosis (ALS). VRG50635 是一种潜在的同类最佳 PIKfyve 小分子抑制剂，是使用 Verge 的人工智能驱动平台 CONVERGE® 发现的。 VRG50635 is a potential best-in-class, small molecule inhibitor of PIKfyve, discovered using CONVERGE®, Verge's AI-powered platform. Ferrer 将获得该药物在欧洲、中南美洲、东南亚和日本的权利，而 Verge 保留美国和其他地区的许可。 Ferrer will acquire the rights for the drug in Europe, Central and South America, Southeast Asia, and Japan, while Verge retains the license for the US and other territories.